These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34622222)

  • 21. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
    Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G
    Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A flow cytometric method to detect apoptosis-related protein expression in minimal residual disease in acute myeloid leukemia.
    van Stijn A; Kok A; van der Pol MA; Feller N; Roemen GM; Westra AH; Ossenkoppele GJ; Schuurhuis GJ
    Leukemia; 2003 Apr; 17(4):780-6. PubMed ID: 12682637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Universal monitoring of minimal residual disease in acute myeloid leukemia.
    Coustan-Smith E; Song G; Shurtleff S; Yeoh AE; Chng WJ; Chen SP; Rubnitz JE; Pui CH; Downing JR; Campana D
    JCI Insight; 2018 May; 3(9):. PubMed ID: 29720577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measurable residual disease in acute myeloid leukemia using flow cytometry: approaches for harmonization/standardization.
    Schuurhuis GJ; Ossenkoppele GJ; Kelder A; Cloos J
    Expert Rev Hematol; 2018 Dec; 11(12):921-935. PubMed ID: 30466339
    [No Abstract]   [Full Text] [Related]  

  • 25. Minimal residual disease in acute myeloid leukemia--current status and future perspectives.
    Kayser S; Walter RB; Stock W; Schlenk RF
    Curr Hematol Malig Rep; 2015 Jun; 10(2):132-44. PubMed ID: 25994952
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Minimal Residual Disease in Acute Myeloid Leukemia.
    Gomez-Arteaga A; Guzman ML
    Adv Exp Med Biol; 2018; 1100():111-125. PubMed ID: 30411263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia.
    Al-Mawali A; Gillis D; Lewis I
    Am J Clin Pathol; 2009 Jan; 131(1):16-26. PubMed ID: 19095561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Prognosticating relapse risk based on multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia].
    Wan SG; Zhao H; Sun XJ; He JJ; Su L; Xu J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):557-62. PubMed ID: 19549363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Minimal residual disease after allogeneic stem cell transplant: a comparison among multiparametric flow cytometry, Wilms tumor 1 expression and chimerism status (Complete chimerism versus Low Level Mixed Chimerism) in acute leukemia.
    Rossi G; Carella AM; Minervini MM; Savino L; Fontana A; Pellegrini F; Greco MM; Merla E; Quarta G; Loseto G; Capalbo S; Palumbo G; Cascavilla N
    Leuk Lymphoma; 2013 Dec; 54(12):2660-6. PubMed ID: 23547840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Minimal Residual Disease in Acute Myeloid Leukemia.
    Sung PJ; Luger SM
    Curr Treat Options Oncol; 2017 Jan; 18(1):1. PubMed ID: 28110381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single-cell mutational profiling enhances the clinical evaluation of AML MRD.
    Ediriwickrema A; Aleshin A; Reiter JG; Corces MR; Köhnke T; Stafford M; Liedtke M; Medeiros BC; Majeti R
    Blood Adv; 2020 Mar; 4(5):943-952. PubMed ID: 32150611
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.
    Terwijn M; van Putten WL; Kelder A; van der Velden VH; Brooimans RA; Pabst T; Maertens J; Boeckx N; de Greef GE; Valk PJ; Preijers FW; Huijgens PC; Dräger AM; Schanz U; Jongen-Lavrecic M; Biemond BJ; Passweg JR; van Gelder M; Wijermans P; Graux C; Bargetzi M; Legdeur MC; Kuball J; de Weerdt O; Chalandon Y; Hess U; Verdonck LF; Gratama JW; Oussoren YJ; Scholten WJ; Slomp J; Snel AN; Vekemans MC; Löwenberg B; Ossenkoppele GJ; Schuurhuis GJ
    J Clin Oncol; 2013 Nov; 31(31):3889-97. PubMed ID: 24062400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells.
    Han L; Qiu P; Zeng Z; Jorgensen JL; Mak DH; Burks JK; Schober W; McQueen TJ; Cortes J; Tanner SD; Roboz GJ; Kantarjian HM; Kornblau SM; Guzman ML; Andreeff M; Konopleva M
    Cytometry A; 2015 Apr; 87(4):346-56. PubMed ID: 25598437
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia.
    Appelbaum FR
    Best Pract Res Clin Haematol; 2013 Sep; 26(3):279-84. PubMed ID: 24309531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.
    Platzbecker U; Middeke JM; Sockel K; Herbst R; Wolf D; Baldus CD; Oelschlägel U; Mütherig A; Fransecky L; Noppeney R; Bug G; Götze KS; Krämer A; Bochtler T; Stelljes M; Groth C; Schubert A; Mende M; Stölzel F; Borkmann C; Kubasch AS; von Bonin M; Serve H; Hänel M; Dührsen U; Schetelig J; Röllig C; Kramer M; Ehninger G; Bornhäuser M; Thiede C
    Lancet Oncol; 2018 Dec; 19(12):1668-1679. PubMed ID: 30442503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Standardized flow-cytometry-based protocol to simultaneously measure transcription factor levels.
    Manso BA; Medina KL
    STAR Protoc; 2021 Jun; 2(2):100485. PubMed ID: 34041499
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Studying clonal evolution of myeloid malignancies using induced pluripotent stem cells.
    Doulatov S; Papapetrou EP
    Curr Opin Hematol; 2021 Jan; 28(1):50-56. PubMed ID: 33264225
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical and biological prognostic factors in relapsed acute myeloid leukemia patients].
    Yébenes-Ramírez M; Serrano J; Martínez-Losada C; Sánchez-García J
    Med Clin (Barc); 2016 Sep; 147(5):185-191. PubMed ID: 27374030
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up.
    Boyer T; Gonzales F; Plesa A; Peyrouze P; Barthelemy A; Guihard S; Quesnel B; Roumier C; Preudhomme C; Cheok M
    J Vis Exp; 2018 Mar; (133):. PubMed ID: 29630051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ClonEvol: clonal ordering and visualization in cancer sequencing.
    Dang HX; White BS; Foltz SM; Miller CA; Luo J; Fields RC; Maher CA
    Ann Oncol; 2017 Dec; 28(12):3076-3082. PubMed ID: 28950321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.